PubRank

Tarek Hassanein

Author PubWeight™ 66.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013 13.30
2 Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014 9.25
3 ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014 4.90
4 Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014 3.40
5 Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013 3.40
6 Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009 3.31
7 Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013 3.30
8 Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003 2.18
9 Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009 2.02
10 Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol 2006 1.74
11 Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol 2008 1.47
12 Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010 1.47
13 Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 2005 1.39
14 Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007 1.12
15 Use of orlistat (xenical) to treat chylous ascites. J Clin Gastroenterol 2005 1.00
16 Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012 0.97
17 Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med 2016 0.97
18 Domino liver transplantation in maple syrup urine disease. Liver Transpl 2006 0.94
19 Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2013 0.90
20 Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment. J Neurovirol 2014 0.89
21 Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004 0.88
22 Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology 2010 0.86
23 YKL-40 expression in human hepatocellular carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int 2011 0.86
24 Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging 2007 0.85
25 Transjugular intrahepatic portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in a patient with cirrhosis. J Vasc Interv Radiol 2004 0.84
26 Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast-enhanced magnetic resonance images. J Magn Reson Imaging 2012 0.83
27 Ultrasound system to measure esophageal varix pressure: an in vitro validation study. Am J Physiol Gastrointest Liver Physiol 2004 0.83
28 Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2008 0.81
29 Hepatitis C infection, Cognition, and inflammation in an Egyptian sample. J Med Virol 2011 0.81
30 Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther 2015 0.80
31 The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. Gastroenterol Hepatol (N Y) 2008 0.79
32 Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr 2011 0.77
33 Assessment and usefulness of clinical scales for semiquantification of overt hepatic encephalopathy. Clin Liver Dis 2012 0.76
34 Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol 2016 0.75
35 Eradicating hepatitis C virus: The APRN's role. Nurse Pract 2019 0.75
36 The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver Int 2003 0.75
37 Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017 0.75